Market news

Syndax achieved FDA approval for Revuforj in r/r mNPM1 AML and is pursuing pivotal studies to expand into 1st-line AML populations. Read why SNDX is a Strong Buy.

Syndax Pharmaceuticals, Inc. has an attractive valuation, key readouts in Q4, and an expanding pipeline. Read more on SNDX stock here.

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting comm

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Citi 2026 Biopharma Back to School Conference in New York, NY with a fireside chat on Thursday, September 10, 2026, at 8:40 a.m. ET.H.C. Wainwright 28t

Syndax Pharmaceuticals Inc (SNDX) has an average rating of buy and mean price target of $37.55, acco

Syndax Pharmaceuticals (NASDAQ:SNDX) just posted a quarter that nearly doubled revenue, yet shares slipped 2.41% anyway. On its August 4 earnings call, management reported combined sales of $115 million across its two approved drugs, both now annualizing above $200 million a year. So why didn’t the market cheer? The answer sits inside the details investors […]

Detailed price information for Syndax Pharma (SNDX-Q) from The Globe and Mail including charting and trades.

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2026, the Company granted inducement awards to purchase up to 59,250 shares of common stock to five new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement

Syndax (SNDX) delivered earnings and revenue surprises of -22.22% and -11.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo™ (axatilimab-csfr) net revenue of $60.3 million in 2Q26, a 67% year-over-year increase, resulting in Syndax collaboration revenue of $18.1 million – – Expanded pipeline with a novel, mutant-selective, allosteric EGFR inhibitor for NSCLC and an internally developed next-generation menin inhibitor for myelofibrosis – – Topl

Syndax Pharmaceuticals (NASDAQ:SNDX) reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, as sales of its leukemia treatment Revuforj and chronic graft-versus-host disease therapy Niktimvo continued to grow. Chief Executive Officer Michael Metzger said the

Syndax: Q2 Earnings Snapshot

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2026 financial results and provide a business update on Tuesday, August 4, 2026. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, August 4, 2026. The live audio webcast and accompanying s

Detailed price information for Syndax Pharma (SNDX-Q) from The Globe and Mail including charting and trades.

Does Syndax Pharmaceuticals (SNDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Detailed price information for Hca Holdings Inc (HCA-N) from The Globe and Mail including charting and trades.

Syndax Pharmaceuticals (NASDAQ:SNDX) used a company R&D event to outline expansion plans for its approved medicines Revuforj and Niktimvo while introducing two pipeline assets aimed at non-small cell lung cancer and myelofibrosis. Chief Executive Officer Michael Metzger said the company is now

The consensus price target hints at a 70.4% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs – – SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF – – SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new ar